Delay in Insurance Approval of Biologic Therapy Dose Escalation Is Associated With Increased Disease Activity in Patients With Inflammatory Bowel Disease

被引：0
|
作者：
Shah, Nisha [1 ]
Cherry, Laura [1 ]
Zuckerman, Autumn [1 ]
Vimalathas, Praveen [1 ]
Choi, Leena [1 ]
Donoho, Charles A. [1 ]
Pabla, Baldeep [1 ]
Scoville, Elizabeth [1 ]
Dalal, Robin [1 ]
Beaulieu, Dawn [1 ]
Schwartz, David [1 ]
Horst, Sara [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S833
引用
收藏
页码：S385 / S385
页数：1
相关论文
共 50 条
  • [21] Predictors of Vedolizumab Dose Escalation or Cessation in Inflammatory Bowel Disease Patients
    Razvi, Mohammed A.
    Chowdhury, Reezwana
    Parian, Alyssa
    Melia, Joanna
    Truta, Brindusa
    Brant, Steve
    Dudley-Brown, Sharon
    Lazarev, Mark
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S417 - S418
  • [22] Age is not Associated With Adverse Events From Biologic Therapy in Patients With Inflammatory Bowel Disease
    Bhushan, Anita
    Pardi, Darrell S.
    Loftus, Edward V.
    Tremaine, William J.
    Kammer, Patricia P.
    Thapa, Prabin
    Harmsen, William S.
    Zinsmeister, Alan R.
    Sandborn, William J.
    GASTROENTEROLOGY, 2010, 138 (05) : S62 - S62
  • [23] Disease Activity Is Associated With Increased Bacterial Diversity in Inflammatory Bowel Disease
    Docktor, Michael
    Wang, Yaoyu
    Abramowicz, Shelly
    Weber, Sarah
    Boisvert, Heike
    Duncan, Margaret
    Bousvaros, Athos
    Paster, Bruce
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S63 - S63
  • [24] Discussion on the biologic therapy of inflammatory bowel disease
    Merger, M
    Herfarth, H
    Scholmerich, J
    Andus, T
    Färber, L
    GASTROENTEROLOGY, 2003, 124 (07) : 2005 - 2006
  • [25] Biologic Therapy in Inflammatory Bowel Disease Preface
    Loftus, Edward V., Jr.
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2014, 43 (03) : XV - XVII
  • [26] Colonic Lymphomas Associated with Biologic and Immunomodulator Therapy for Inflammatory Bowel Disease
    Jennings, Joseph
    Monzur, Farah
    Mattar, Mark
    Charabaty, Aline
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2013, 108 : S504 - S504
  • [27] Endoscopic Disease Activity and Biologic Therapy Predict Quality of Bowel Preparation for Colonoscopies in Inflammatory Bowel Disease
    Shenoy, Vinayak
    Kumar, Anand
    Buckley, Megan C.
    Durbin, Laura
    Mackey, James
    Mone, Anjali
    Swaminath, Arun
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S382 - S382
  • [28] Endoscopic Disease Activity and Biologic Therapy Are Independent Predictors of Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy
    Kumar, Anand
    Shenoy, Vinayak
    Buckley, Megan C.
    Durbin, Laura
    Mackey, James
    Mone, Anjali
    Swaminath, Arun
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (10) : 4851 - 4865
  • [29] Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease
    Yadav, Abhijeet
    Foromera, Joshua
    Feuerstein, Ilana
    Falchuk, Kenneth R.
    Feuerstein, Joseph D.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (06) : 853 - 857
  • [30] Endoscopic Disease Activity and Biologic Therapy Are Independent Predictors of Suboptimal Bowel Preparation in Patients with Inflammatory Bowel Disease Undergoing Colonoscopy
    Anand Kumar
    Vinayak Shenoy
    Megan C. Buckley
    Laura Durbin
    James Mackey
    Anjali Mone
    Arun Swaminath
    Digestive Diseases and Sciences, 2022, 67 : 4851 - 4865
12345